In vivo Efficacy Models
Therapeutic Efficacy Models - Antibacterial
UNTHSC Pre-Clinical Services currently offers the following protocols. Additional protocols can be developed and validated to meet the individual requirements of the Sponsor.
Septicemia Infection (Mouse)
ED50 determinations for experimental molecules against infections with both gram-positive and gram-negative pathogens, including characterized resistant strains.
Subcutaneous Abscess (Mouse)
A chronic skin infection model involving either Staphylococcal (MRSA / MRSE), Streptococcal (pyogenes) or Pseudomonas aeruginosa bacterial isolates.
Superficial Skin Infection Model (Mouse)
A superficial skin infection model for the assessment of topical applications involving either Staphylococcus aureus, Streptococcus pyogenes or Pseudomonas aeruginosa infections.
Biofilm Catheter Implant (Mouse)
Model of device-related biofilm infection using subcutaneous S. aureus infected teflon catheter implants.
Lung Infection (Mouse)
Murine lung infections with S. aureus, S. pneumoniae, K. pneumoniae, A. baumannii, P. aeruginosa and H. infuenzae using survival (multiple dose regimen) or lung CFU (single dose) as measured endpoints.
Central Venous Catheter Infection (Rat)
Biofilm-like infection of an intravascular indwelling jugular catheter with S. aureus.
Granuloma Pouch (Rat / Mouse)
Infected pouch model for the simultaneous determination of penetration (levels) and efficacy (CFU counts) of administered agents in the rat or mouse.
Helicobacter pylori Gastritis (Mouse)
Gastric infection model using H. pylori SS1 strain with efficacy measured as CFU log reduction / relapse.
C. difficile Infection (Hamster)
Experimental CDAD model for the evaluation of survival / relapse, GI pharmacokinetics and Tox A/B detection utilizing both susceptible and epidemic (Ribotypes 027 & 078) clinical isolates.
Neutropenic Thigh Infection Model (Mouse)
Determination of the Pharmacokinetic / Pharmacodynamic indices as related to the efficacy of an antimicrobial agent (pharmacokinetics, dose ranging and dose fractionation studies).
Urinary Tract Infection (Mouse)
Ascending pyelonephritis model using a uropathogenic E. coli bacterial isolate and the diabetic mouse UTI model with Pseudomonas aeruginosa; enumeration of the bacterial infection in kidneys, bladder and urine.
Sepsis / Inflammation (Mouse)
Murine cecal ligation and puncture model (CLP) with survival and biomarker endpoints.
Intra-abdominal Abscess Model (Rat / Mouse)
Mixed intra-abdominal infection with E. coli and B. fragilis
Infective Endocarditis Model (Rat)
S. aureus, Enterococcus
Systemic Antifungal Model (Mouse)
C. albicans (candidiasis)
Aerosol drug delivery for therapeutic efficacy models, C. difficile GI infection in the mouse.
Additional Protocols / Procedures
Protocols of interest can be developed for sponsor as required.